Ok Biotech Co Ltd (4155) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of Ok Biotech Co Ltd stock TWD 13.81, price TWD 18.50, that is 25.4% below the price, quality 48 out of 100. Rating: overvalued. Calculated from audited financials with 16 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.
How to read this chart
60‑month range 13.45 TWD – 38.90 TWD · fair‑value band 11.61 TWD – 17.11 TWD · the 18.50 TWD price screens above the 13.81 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.
Follow Ok Biotech Co in your weekly email
Every Wednesday you see whether Ok Biotech Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
OK Biotech Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, and sale of blood glucose monitoring systems and homecare healthcare devices in Taiwan, the rest of Asia, America, Africa, and Europe.
Show moreShow less
The company offers nebulizers, blood glucose meters, glucometers, blood sugar meters, and blood glucose test strips. It also provides OTC hearing aids, multi-frequency therapy devices, and factory setup solutions, as well as professional OEM/ODM customized services.
The company sells its products under the OKB and Prodigy brands. OK Biotech Co., Ltd. was incorporated in 2004 and is headquartered in Hsinchu City, Taiwan.
Stock analysis
Ok Biotech Co Ltd (4155) currently trades at 18.50 TWD, while our model-based Fair Value estimate is 13.81 TWD, 25% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 13.72 TWD per share, and 2 of the 16 models we run sit above the 18.50 TWD price.
Bear case: the Dividend Discount group reads lowest at 4.58 TWD, and 14 of the 16 models stay below the price. Data coverage for this calculation is low.
Scenario range: 11.61 TWD (bear) to 17.11 TWD (bull), the price of 18.50 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector.
Weak Growth: Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Ok Biotech Co Ltd reported revenue of 1.6B TWD in FY2025 versus 1.3B TWD in FY2021, a compound +5.4%/yr. Reported net income was 82.4M TWD in FY2025, compounding +27.3%/yr from FY2021.
Key figures
Market cap 2.6B TWD (≈ $79.5M) Micro · P/E ratio 9.8 · P/S ratio 1.52 · EPS (TTM) 1.89 TWD · Dividend yield 1.8% · Net margin 15.8% · Return on equity 10.3% · Return on assets (EBIT) 2.5% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 45 out of 100 (low confidence).
What moves the price
The share trades at its 52-week high and 38% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at −25%, 4155 screens richer than that median.
Fair Value models
Bear11.61 TWDFair Value 13.81 TWDBull17.11 TWD
Price 18.50 TWD · Downside -25.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (1.33 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.20/100
Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Revenue growth 1 year
−6.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.0%
Start year 2020 (pandemic). Over 10 years: +6.2% a year
Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.3%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−15.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year−17.4%
Dividend (yield on the price)1.8%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−17.4% vs −8.9%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.12% → 7%
Pace: the 5-year rate starts in 2020 (pandemic)
⚠ Revenue per share shrinking 3.0%/yr over ~10Y (margins eroding too) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 318 stocks
Beats the industry median on 9/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score48 · Below median
Fair Value upside−25.4% · Below median
Profitability
Return on equity (12 months)10.3% · Above median
Return on assets2.1% · Above median
Net margin (12 months)15.8% · Top 25%
Operating margin (12 months)11.9% · Above median
Growth and dividend
Revenue growth (quarter YoY)2.2% · Below median
Dividend yield (12 months)1.8% · Above median
Balance sheet
Debt / equity0.24× · Above median
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/E (12 months)9.8× · Cheapest 25%
P/B0.93× · Cheapest 25%
P/S (12 months)1.52× · Cheaper than median
EV/EBITDA8.8× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 6
FUTURE (revenue growth)11· sector 36
PAST (return on equity)41· sector 17
HEALTH (low debt)88· sector 98
DIVIDEND (yield)36· sector 34
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Ok Biotech Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/4155
Frequently asked questions
Is Ok Biotech Co Ltd (4155) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of 13.81 TWD versus a price of 18.50 TWD, about 25% lower (overvalued).
What is the fair value of 4155?
Our model-based fair value for Ok Biotech Co Ltd is 13.81 TWD (as of Nov 9, 2026), built from audited fundamentals. The current price: 18.50 TWD.
What is the quality score of 4155?
Ok Biotech Co Ltd has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Ok Biotech Co Ltd (4155)?
Our model-based price target is the fair value of 13.81 TWD (as of Nov 9, 2026) from 16 valuation models. Cautious scenario 11.61 TWD, optimistic scenario 17.11 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Ok Biotech Co Ltd stock forecast for 2026?
Our models put fair value at 13.81 TWD, about 25% lower versus a price of 18.50 TWD (overvalued). Cautious scenario 11.61 TWD, optimistic scenario 17.11 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Ok Biotech Co Ltd (4155)?
Ok Biotech Co Ltd reported trailing-twelve-month revenue of about 1.5B TWD (latest available figure, as of Nov 9, 2026).
Does Ok Biotech Co Ltd pay a dividend?
Ok Biotech Co Ltd currently shows a dividend yield of 1.81% relative to its recent price (as of Nov 9, 2026).
How much is the dividend of Ok Biotech Co Ltd (4155) and when is the ex-dividend date?
Ok Biotech Co Ltd pays a dividend of 0.335 TWD per share a year, a dividend yield of 1.8%. The last ex-dividend date was Oct 20, 2026. A dividend has been paid every year since at least 2013. The payout ratio is 17.7% of earnings. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What is the intrinsic value of Ok Biotech Co Ltd (4155)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Ok Biotech Co Ltd it is 13.81 TWD per share (as of Nov 9, 2026), against a price of 18.50 TWD. It is the blended result of 16 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Ok Biotech Co Ltd stock overvalued or undervalued in 2026?
As of Nov 9, 2026, 4155 trades above its calculated fair value: price 18.50 TWD, fair value 13.81 TWD, a gap of about −25% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 4155?
No. The price is what the market pays today (18.50 TWD); the fair value is what the company's own numbers justify (13.81 TWD). For Ok Biotech Co Ltd the two are 4.69 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Ok Biotech Co Ltd worth?
The market values Ok Biotech Co Ltd at about 2.6B TWD (market capitalisation, as of Nov 9, 2026). Per share that is 18.50 TWD; our models calculate a fair value of 13.81 TWD per share.
What do the bullish and bearish scenarios say about 4155?
Our models span a range for Ok Biotech Co Ltd: cautious scenario 11.61 TWD, base 13.81 TWD, optimistic 17.11 TWD per share (as of Nov 9, 2026, price 18.50 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 4155?
Ok Biotech Co Ltd trades at a price-to-earnings ratio of 9.8 (as of Nov 9, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 13.81 TWD is built from several models across several years. Other multiples: P/B 0.9, P/S 1.5, EV/EBITDA 8.8.
How solid is the balance sheet of Ok Biotech Co Ltd (4155)?
Balance-sheet figures for Ok Biotech Co Ltd (as of Nov 9, 2026): return on equity 10.3%, debt of 0.24 per unit of equity. They feed the Quality Score of 48/100, which measures business quality independently of the share price.
How far is 4155 from its 52-week high?
Ok Biotech Co Ltd trades at 18.50 TWD, at its 52-week high of 18.50 TWD and 38% above the low of 13.45 TWD (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 13.81 TWD is for.
Which stocks are comparable to Ok Biotech Co Ltd?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Ok Biotech Co Ltd stock attractive at the current price?
The data as of Nov 9, 2026: price 18.50 TWD, calculated fair value 13.81 TWD (−25%), Quality Score 48/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 4155 calculated?
We run Ok Biotech Co Ltd through 16 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 13.81 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Ok Biotech Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Ok Biotech Co Ltd (4155)?
The closing price on Nov 9, 2026 was 18.50 TWD. Our model-based fair value is 13.81 TWD, about 25% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Ok Biotech Co Ltd right now?
The price sits above even our optimistic bull case (17.11 TWD). The favourable scenario is already priced in. Weak quality (48/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Where does the earnings growth of Ok Biotech Co Ltd (4155) come from?
Earnings per share at Ok Biotech Co Ltd grew −8.7 % a year from 2014 to 2025. Broken into its drivers: revenue per share −2.1 %, EBIT margin −7.1 %, tax rate +1.5 %, residual (interest, one-offs) −1.1 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Ok Biotech Co Ltd
How large is the market capitalisation of Ok Biotech Co Ltd (4155)?
The market capitalisation of Ok Biotech Co Ltd is 2.6B TWD (≈ $79.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Ok Biotech Co Ltd (4155)?
The price-to-sales ratio of Ok Biotech Co Ltd is 1.52 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Ok Biotech Co Ltd (4155)?
Earnings per share at Ok Biotech Co Ltd are 1.89 TWD (price ÷ EPS = P/E 9.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Ok Biotech Co Ltd (4155)?
The dividend yield of Ok Biotech Co Ltd is 1.8% (payout 17.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Ok Biotech Co Ltd (4155)?
The net margin of Ok Biotech Co Ltd is 15.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Ok Biotech Co Ltd (4155)?
The return on equity (ROE) of Ok Biotech Co Ltd is 10.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Ok Biotech Co Ltd (4155)?
On an EBIT basis the return on assets of Ok Biotech Co Ltd is 2.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Ok Biotech Co Ltd (4155)?
The operating margin of Ok Biotech Co Ltd is 11.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Ok Biotech Co Ltd (4155)?
Revenue at Ok Biotech Co Ltd is growing +2.2% versus a year earlier (3y avg +1.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Ok Biotech Co Ltd (4155)?
Earnings per share at Ok Biotech Co Ltd are growing +128% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Ok Biotech Co Ltd (4155) generate?
The free cash flow of Ok Biotech Co Ltd is −89.6M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Ok Biotech Co Ltd (4155) carry?
The net debt of Ok Biotech Co Ltd is 720M TWD (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Ok Biotech Co Ltd in the live analysis
One click puts Ok Biotech Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 9, 2026